Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT and KL-A167 in Neoadjuvant TNBC
NCT07371208Phase 2Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Dec 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, tagitanlimab in triple-negative breast cancer (TNBC), sponsored by Shanghai Jiao Tong University School of Medicine. Started Dec 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07371208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371208.